Sandusky, OH, Jan. 28, 2022 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) at present launched a 2022 strategic replace on the corporate’s CBD pharmaceutical and nutraceutical improvement technique. The replace is included in its entirety beneath:
PAO Group, Inc. is an rising hashish and CBD firm focusing on development by way of two tracks – pharmaceutical and nutraceutical. The Firm is growing a hashish extract-based remedy to deal with varied respiratory ailments and diseases together with COPD. Latest impartial research has confirmed PAOG’s earlier conclusions that CBD may additionally be a viable therapy for COVID-19.
PAOG has positioned itself as an rising CBD Biopharma firm on a improvement path to deal with varied and main respiratory ailments that characterize billions in potential market sizes.
The Firm has engaged a CRO to provoke the method for potential FDA approval of RespRx, its new flagship COPD therapy. COPD represents an estimated $14.1B market by 2025.
The World Well being Group estimates 65 million individuals worldwide are bothered with reasonable to extreme COPD and GlobalData forecasts that the COPD therapy market will attain $14.1 billion by 2025. POAG, preclinical research on COPD sufferers had been carried out to guage the affect of its pharmaceutical grade hashish extracts together with different therapies. Favorable outcomes have triggered the deliberate PAOG improvement of this CBD-derived Biopharma product. PAOG has enter into an settlement with a Contract Analysis Group (CRO) as a primary step towards initiating an Investigational New Drug Software (IND) to begin the method for acquiring FDA approval for its RespRx as a COPD therapy.
PAOG acquired the proprietary formulations derived from a patented hashish extraction course of – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
With the patented mental property (IP) to incorporate the prevailing and ongoing analysis and improvement, and favorable preclinical research, administration’s over-lapping tracks is the event of a CBD Biopharma therapy for a number of respiratory-related ailments, notably COPD, COVID-19, and others.
In preclinical research, experiments to guage the potential of hashish extracts derived from the patented extraction course of within the therapy of respiratory ailments had been carried out. The experiments had been designed to guage pure hashish extracts and hashish extracts together with different therapies within the therapy of persistent obstructive pulmonary illness (COPD) and Bronchial asthma. There are a big variety of genes related to COPD and Bronchial asthma. The experiments evaluated the power of assorted formulations to vary Bronchial asthma or COPD related gene expressions in human small airway epithelial cells. A hashish extract alone demonstrated outstanding exercise in gene arrays by up- or down-regulating particular person genes by as a lot as 200-fold. Genes showing particularly delicate to the introduction of hashish extract had been related to irritation, therapeutic and most cancers inhibition. Outcomes from this collection of experiments supplied a baseline for comparability with knowledge from subsequent research, together with a physiological examine.
Whereas the information behind PAOG’s pharmaceutical analysis is powerful and administration is assured within the potential of the proprietary expertise to lead to an FDA authorised therapy, administration acknowledges the trail to income is lengthy and never with out substantial expense.
In accordance, PAOG has initiated a nutraceutical improvement technique constructing on the identical proprietary expertise driving its pharmaceutical developments. The nutraceutical improvement technique is anticipated to drive fast income development and offset the pharmaceutical improvement bills.
PAOG has already launched its personal impartial line of CBD nutraceutical merchandise beneath its “RX” label accessible on the market on North American Hashish Inc.’s (OTC Pink: USMJ) ecommerce web site www.usmj.com. PAOG expects to quickly be including to the “RX” CBD nutraceutical product line.
PAOG has additionally just lately introduced the event of a brand new line of CBD nutraceutical merchandise for Puration, Inc. (OTC Pink: PURA) now underway. PAOG additionally expects to make a strategic announcement with PURA relating to a brand new partnership on CBD nutraceutical manufacturing assets.
With the strategic overview supplied at present, PAOG administration plans to observe up with a lot of updates offering extra element on particular elements of the strategic plan overviewed right here at present main first with the anticipated joint announcement with PURA on the brand new nutraceutical manufacturing useful resource.
Be taught extra about PAOG at www.paogroupinc.com.
Disclaimer:
This Information Launch incorporates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements contain identified and unknown dangers, uncertainties and different essential components that would trigger our precise outcomes, efficiency or achievements, or trade outcomes, to vary materially from any these statements. You might be cautioned to not place undue reliance on any these forward-looking statements. Besides as in any other case required by the federal securities legal guidelines, we undertake no obligation to publicly replace or revise any forward-looking statements after the date of this information launch. None of such forward-looking statements ought to be considered a illustration by us or another individual that the aims and plans set forth on this Information Launch will likely be achieved or be executed.
For Extra Info Contact:
Jim DiPrima
888-272-6472
[email protected]
